The commercial market for developing new antibiotics faces severe structural challenges, threatening global health due to rising antimicrobial resistance. Because new antibiotics must be used sparingly to preserve efficacy and are priced relatively low for short courses of treatment, pharmaceutical companies struggle to generate a viable return on investment. As large drugmakers exit the sector and small biotechs face insolvency, health experts and governments are exploring new economic mechanisms, including subscription-style reimbursement models, to incentivize research and development without relying on high sales volumes.
Antimicrobial resistance poses a growing global health risk as bacteria evolve resistance to existing treatments.
Antibiotics generate low commercial returns because they are prescribed for short durations and held in reserve to prevent resistance, unlike daily medications for chronic illnesses.
High development costs and low revenues have led major pharmaceutical corporations to downsize or abandon antibiotic research divisions.
Several biotechnology startups that successfully developed and gained regulatory approval for new antibiotics have collapsed financially due to limited market uptake.
Subscription-style payment models, often compared to a “Netflix model,” are being implemented to pay manufacturers fixed annual fees regardless of how many doses are prescribed.
Health policy experts advocate for expanded market entry rewards and public-private funding initiatives to ensure a stable pipeline of novel antimicrobial drugs.
The Financial Times is a British daily business newspaper printed in broadsheet and also published digitally that focuses on business and economic current affairs.
The Financial Times is a British daily broadsheet and digital newspaper globally recognized for its authoritative coverage of business, economics, and international political affairs. Currently owned by the Japanese holding company Nikkei, the FT is easily identified in print by its distinctive salmon-pink paper. It targets an audience of global business leaders, policymakers, and financial professionals, relying heavily on a successful premium digital subscription model.
